[SCHEDULE 13G/A] Ocuphire Pharma, Inc. Common Stock SEC Filing

Rhea-AI Filing Summary

Opus Genetics, Inc. disclosed that Nantahala Capital Management, LLC and two individuals associated with it each may be deemed the beneficial owner of 6,250,299 shares of the company’s common stock, representing 9.99% of the class. The reported total includes 2,904,378 shares that may be acquired within 60 days upon exercise of warrants, and all reported shares are held with shared voting and dispositive power (no sole voting or dispositive power). The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control. A fund advised by Nantahala, Blackwell Partners LLC - Series A, has the right to receive dividends or sale proceeds for more than 5% of the reported shares.

Positive

• Clear disclosure of share count and percent ownership (6,250,299 shares; 9.99%)
• Includes exercisable warrants in the reported total (2,904,378 shares), clarifying potential near-term conversion

Negative

• Concentration near 10% could be dilutive or influential if warrants are exercised
• Shared voting power only means no single reporting person has sole control, which may obscure decision-making authority

Insights

Institutional Ownership Analyst

TL;DR: Nantahala reports a near-10% position in Opus Genetics comprised partly of exercisable warrants, disclosed as held in the ordinary course.

The Schedule 13G shows a materially significant passive stake: 6,250,299 shares equal to 9.99% of outstanding common stock, including 2,904,378 shares exercisable via warrants within 60 days. Ownership is reported with shared voting and dispositive power, indicating control is exercised collectively through the adviser and principals rather than individually. The certification that holdings are ordinary-course and not intended to influence control limits immediate governance implications, but the size and warrant exposure could affect dilution and voting outcomes if exercised.

Corporate Governance Specialist

TL;DR: Disclosure signals a significant passive investor position with potential near-term conversion risk from warrants.

The filing classifies Nantahala as an investment adviser and lists two principals as control persons for purposes of disclosure. Shared voting/dispositive power across the reporting persons suggests coordinated reporting rather than a single controlling holder. The note identifying Blackwell Partners LLC - Series A as having rights to dividends or proceeds for more than 5% of the reported shares clarifies beneficial interests among related funds. No statements in the filing indicate intent to seek board representation or change control, keeping this disclosure within routine large-holder transparency rather than an activist signal.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Opus Genetics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

67577R102

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 67577R102

1

Names of Reporting Persons

Nantahala Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,250,299.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,250,299.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,250,299.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 67577R102

1

Names of Reporting Persons

Wilmot B. Harkey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,250,299.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,250,299.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,250,299.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 67577R102

1

Names of Reporting Persons

Daniel Mack

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,250,299.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,250,299.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,250,299.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Opus Genetics, Inc.
(b)	Address of issuer's principal executive offices: 8 DAVIS DRIVE SUITE 220 DURHAM, NORTH CAROLINA, 27709
Item 2.
(a)	Name of person filing: (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
(b)	Address or principal business office or, if none, residence: 130 Main St. 2nd Floor, New Canaan, Connecticut 06840
(c)	Citizenship: (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 67577R102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of June 30, 2025, Nantahala may be deemed to be the beneficial owner of 6,250,299 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 6,250,299 Shares includes 2,904,378 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
(b)	Percent of class: As of June 30, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 9.99% (2) Wilmot B. Harkey: 9.99% (3) Daniel Mack: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(ii) Shared power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 6,250,299 Shares. (2) Wilmot B. Harkey: 6,250,299 Shares. (3) Daniel Mack: 6,250,299 Shares.
	(iii) Sole power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(iv) Shared power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 6,250,299 Shares. (2) Wilmot B. Harkey: 6,250,299 Shares. (3) Daniel Mack: 6,250,299 Shares.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nantahala Capital Management, LLC

Signature:	/s/ Taki Vasilakis
Name/Title:	Taki Vasilakis / Chief Compliance Officer
Date:	08/14/2025

Wilmot B. Harkey

Signature:	/s/ Wilmot B. Harkey
Name/Title:	Wilmot B. Harkey
Date:	08/14/2025

Daniel Mack

Signature:	/s/ Daniel Mack
Name/Title:	Daniel Mack
Date:	08/14/2025

FAQ

How many Opus Genetics shares does Nantahala Capital Management report owning?

The filing reports 6,250,299 shares beneficially owned by Nantahala and the two reporting individuals, representing 9.99% of the class.

Does the reported ownership include shares from warrants?

Yes. The total includes 2,904,378 shares that may be acquired within sixty days upon exercise of warrants.

Do any of the reporting persons have sole voting or dispositive power over the shares?

No. The filing states 0 shares for sole voting and sole dispositive power; all reported shares are held with shared voting and dispositive power.

Is the stake reported as intended to influence control of Opus Genetics?

No. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Which affiliated fund has rights to dividends or sale proceeds for part of the reported position?

The filing identifies Blackwell Partners LLC - Series A, a fund advised by Nantahala, as having rights to receive dividends or proceeds for more than 5% of the reported shares.